Kechuang Biotech has completed all the listing procedures, and the launch date is scheduled for October 8, the first working day after the long holiday.

The agency has obtained the shipment volume of China’s brain-computer connected mobile phones in the third quarter.

As one of the shareholders of Kechuang Biotech, IDG lists brain-computer connected mobile phones separately in its internal smartphone shipment report for calculation.

According to statistics, shipments of brain-computer connected mobile phones in the first three quarters of 2021 were 4.71 million units, far exceeding expectations.

Because Mi Mix4, the first brain-computer connected mobile phone, was only launched for sale in June. It only took a quarter for the brain-computer connected mobile phone to be sold.

The internal expectation of the organization is that the shipment volume of brain-computer connected mobile phones in 2022 will be around 20 million units. This result can be said to be excellent.

You must know that in the third quarter of 2021, Apple, the largest player in high-end brands, has not yet released its brain-computer connected mobile phone.

The production capacity of brain-computer-connected mobile phones has exceeded expectations, although not by much.

The time for Apple’s fall conference this year has not yet been set, but Cook has already started to build momentum on Twitter:

“The new iPhone is an incredible product!”

"I can't wait to use it for you."

Due to technical limitations, brain-computer connected mobile phones are basically only sold in China. Foreign consumers who want to use it must either purchase goods or purchase them on behalf of others.

As a result, a complete industrial chain has been formed from the purchase of brain-computer connection mobile phones in China to Amerikan, Europa and other places.

Although the recognition accuracy of English-speaking or other language-speaking people using brain-computer connection with mobile phones is only 70%, it cannot stand up to wealthy European and American electronic product enthusiasts.

For only about 200 more yuan, you can enjoy the brain-computer connection function. The brain-computer connection device is not much different from headphones, which is completely acceptable to them.

Cook’s tweet below is full of ridicule:

“Another special offer from China”

“Apple only cares about the Chinese market”

"It is indeed very convenient to connect the brain-computer to the mobile phone. I have a good experience using the brain-computer connected to the mobile phone made in China. It would be great if the accuracy could be higher. When will the development of American's products be completed?"

Because the shipments of brain-computer connected mobile phones exceeded expectations, the agency's internal valuation of Kechuang Biotech has been raised to a higher level.

"If we consider the long term, Kechuang Biotech can be bought without any thought at a price below 3,000 yuan."

"Considering the short term, as long as the price does not exceed 2,000 yuan on the day of listing, we can build a partial position." A fund manager said at an internal investment research meeting.

"What if the price was directly increased to 3,000 yuan on the first day of listing?" asked his assistant.

"Then let's wait until he falls, and we won't be in a hurry to build a position."

"Unless we can get inside information and know the research and development progress of science and technology in the field of brain-computer connection." The fund manager was thinking: "It should not be that difficult in theory. According to my understanding, it should be fast."

"It's a pity that our market is too big to be aggressive. If it were a private placement price of 3,000 yuan, they would dare to charge it."

The assistant nodded and said: "Since the R&D center of Kechuang Biotech in Lion City was stolen, they have replaced a group of security guards and found a domestic security company in Lion City."

"It's even harder to find out the news now. Since Zheng Li is in Lion City, the progress of the Lion City R&D Center will not be reported to Suzhou."

The management scale of this fund exceeds 50 billion, which is among the top domestic funds. Compared with Gu Lan, Zhang Kun's scale of 100 billion is not much different.

The larger the management scale, the more restrictions the fund manager's operations are subject to. Zhang Kun's rules only allow about a hundred stocks to be bought and sold.

Basically, you can only buy large-cap stocks and blue-chip stocks.

The fund manager feels a headache: "If Kechuang Biotech's brain-computer connection technology makes progress before the first half of next year, whether it is the completion of research and development of English-language products, or the brain-computer connection has new applications in the medical field."

"I think there's huge room for growth."

...

With the listing of Kechuang Biotechnology, Cheng Gang's career also reached its peak. For the first time, he felt that starting a business was such a simple thing.

After just doing some administrative work, Kechuang Biotech is about to go public with a market value of RMB 400 billion, and the secondary market still thinks this price is too cheap.

Cheng Gang has a deeper understanding of technology as the primary productive force. When he started his own business, he failed because his technical advantages were not strong enough.

Since Zheng Li left the Lion City, Cheng Gang has essentially become the number one person at the headquarters of Science and Technology Biotech, and slowly he has begun to compete with Li Miaomiao, Zheng Li's spokesperson in the company.

Since Zheng Li is still the absolute controller of the company, even if Kechuang Biotech is listed, Zheng Li will still hold more than 51% of the shares after the listing.

Therefore, Cheng Gang and Li Miaomiao are still on good terms on the surface, but privately they are competing for the support of the company's middle-level and other senior executives.

Although Zheng Li is far away in the Lion City, he knows everything about the company's situation. Zheng Li also knows what they know, and Zheng Li still knows what they don't know.

On the eve of the listing, financial institutions that wanted to operate in secret not only approached Li Miaomiao, but also other executives of Kechuang Biotech.

Some executives failed to withstand the temptation and chose to accept the sugar-coated bullets from the other party. Zheng Li went directly through official channels without going through anyone and sent the two people for investigation.

After the incident came out, company executives were shocked by Zheng Li's ruthlessness, and the company, which had been a bit undercurrent, became calm again.

Cheng Gang did not dare to do anything to win over senior executives and middle managers. He realized that even if Zheng Li was not around, he would only be a manager and would not become the actual controller of Kechuang Biotechnology.

Realizing that he was still just a manager, Cheng Gang chose to increase his contacts with IDG's Young.

"Young, after Kechuang Biotech is listed, I plan to cash out some of my shares and set up an investment fund in the field of biomedicine."

"We can interact more often then."

If Cheng Gang was just the owner of an investment fund company, Young would definitely not have much contact with him, but Cheng Gang also has another identity - the general manager of Kechuang Biotechnology.

"Recently, a company really wants to make Series C investment, and the funding gap is huge. If you have the funds, you can consider whether to follow the investment," Young said.

When Cheng Gang heard about Series C and then heard about the huge funding gap, he quickly reacted: "Aibo Biotech?"

Young nodded: "Yes, it's Aibo Biotechnology. They want to raise more than 700 million yuan in cash in their C round. Currently, seven funds have led the investment."

"Temasek, Invesco Development Markets Fund, Zhengxin Stock, Hillhouse, Eli Lilly Asia Fund and Yunfeng Capital."

Some people think that angel investment funds established by Internet companies will not invest in the biopharmaceutical industry, but Yunfeng Capital, as the angel investment company of Alima, participated in the C-round lead investment of Alibaba Biotechnology.

Let's put it this way, angel investment only depends on the quality of the project, and there will be no clear standards for what not to invest and what to invest.
Chapter completed!